37 related articles for article (PubMed ID: 2116226)
1. Understanding Anthracycline Cardiotoxicity From Mitochondrial Aspect.
Huang J; Wu R; Chen L; Yang Z; Yan D; Li M
Front Pharmacol; 2022; 13():811406. PubMed ID: 35211017
[TBL] [Abstract][Full Text] [Related]
2. Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers.
Chen D; Kelly C; Haw TJ; Lombard JM; Nordman IIC; Croft AJ; Ngo DTM; Sverdlov AL
Curr Heart Fail Rep; 2021 Dec; 18(6):362-377. PubMed ID: 34731413
[TBL] [Abstract][Full Text] [Related]
3. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.
Stěrba M; Popelová O; Vávrová A; Jirkovský E; Kovaříková P; Geršl V; Simůnek T
Antioxid Redox Signal; 2013 Mar; 18(8):899-929. PubMed ID: 22794198
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
Alderton PM; Gross J; Green MD
Cancer Res; 1992 Jan; 52(1):194-201. PubMed ID: 1727379
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles.
Herman EH; Ferrans VJ; Myers CE; Van Vleet JF
Cancer Res; 1985 Jan; 45(1):276-81. PubMed ID: 3917371
[TBL] [Abstract][Full Text] [Related]
6. Ameliorative effects of ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the cardiotoxicity induced by doxorubicin or by isoproterenol in the mouse.
Flandina C; Sanguedolce R; Rausa L; D'Alessandro N
Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):259-72. PubMed ID: 2128759
[TBL] [Abstract][Full Text] [Related]
7. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187).
Herman EH; Ferrans VJ
Cancer Res; 1981 Sep; 41(9 Pt 1):3436-40. PubMed ID: 6790165
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
9. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
Alderton P; Gross J; Green MD
Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
[TBL] [Abstract][Full Text] [Related]
10. Cytoprotective agents for anthracyclines.
Dorr RT
Semin Oncol; 1996 Aug; 23(4 Suppl 8):23-34. PubMed ID: 8783663
[TBL] [Abstract][Full Text] [Related]
11. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity.
Seifert CF; Nesser ME; Thompson DF
Ann Pharmacother; 1994 Sep; 28(9):1063-72. PubMed ID: 7803884
[TBL] [Abstract][Full Text] [Related]
12. ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: clinical and preclinical studies.
Green MD; Alderton P; Sobol MM; Gross J; Muggia FM; Speyer JL
Cancer Treat Res; 1991; 58():101-17. PubMed ID: 1683780
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]